A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

NCT04714190 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

351

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
HER2 Overexpressing Gastric Carcinoma

Interventions

DRUG: RC48-ADC
DRUG: Paclitaxel injection
DRUG: Irinotecan Hydrochloride Injection
DRUG: Apatinib Mesylate Tablets

Sponsor

RemeGen Co., Ltd.